Last reviewed · How we verify
Paclitaxel + bevacizumab + atezolizumab
This combination uses a chemotherapy agent (paclitaxel) to kill cancer cells, an anti-angiogenic antibody (bevacizumab) to block tumor blood vessel formation, and an immune checkpoint inhibitor (atezolizumab) to enhance anti-tumor immune responses.
This combination uses a chemotherapy agent (paclitaxel) to kill cancer cells, an anti-angiogenic antibody (bevacizumab) to block tumor blood vessel formation, and an immune checkpoint inhibitor (atezolizumab) to enhance anti-tumor immune responses. Used for Non-small cell lung cancer (phase 3 investigation).
At a glance
| Generic name | Paclitaxel + bevacizumab + atezolizumab |
|---|---|
| Sponsor | Japanese Foundation for Cancer Research |
| Drug class | Combination therapy: chemotherapy + anti-angiogenic monoclonal antibody + PD-L1 inhibitor |
| Target | Microtubules (paclitaxel), VEGF pathway (bevacizumab), PD-L1 (atezolizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel stabilizes microtubules to induce apoptosis in rapidly dividing cancer cells. Bevacizumab blocks VEGF signaling to inhibit angiogenesis and reduce tumor vasculature. Atezolizumab blocks PD-L1 on tumor cells and immune cells, releasing the brake on T-cell-mediated anti-tumor immunity. The combination aims to provide synergistic anti-tumor effects through chemotherapy, anti-angiogenesis, and immunotherapy.
Approved indications
- Non-small cell lung cancer (phase 3 investigation)
Common side effects
- Neutropenia
- Anemia
- Peripheral neuropathy
- Hypertension
- Fatigue
- Immune-related adverse events
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (PHASE1)
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (PHASE2)
- An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (PHASE3)
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: